Dendreon (DNDN) Announces Positive PROVENGE Data From PROTECT Study
Dendreon Corporation (Nasdaq: DNDN) presented today data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APCs), a measure of potency, is a correlate of immune activation.
P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
More from Release
P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.
More from Release
You May Also Be Interested In
- Dendreon Announces Webcast Presentations at Upcoming Conferences
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
